ArticleBMC gastroenterology2025
Early acetaminophen administration and mortality outcomes in critically ill patients with cirrhosis: a retrospective analysis from the MIMIC-IV database.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Navigating Chronic Pain in Patients with Cirrhosis: Unique Analgesic Considerations and Non-Pharmacologic Options.Current hepatology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCirrhosis is a major global health burden, often requiring ICU admission due to complications. Acetaminophen (APAP) is frequently used for pain and fever management in critically ill patients, but its safety in cirrhotic patients remains uncertain.
aimsTo evaluate the association between early APAP use and mortality outcomes in ICU patients with cirrhosis.
methodsThis retrospective cohort study used the MIMIC-IV database. Adult cirrhotic patients were divided into two groups based on whether they received APAP within 24 h of ICU admission. The primary outcome was 28-day ICU mortality; secondary outcomes included 7-day, 60-day, in-hospital, and overall ICU mortality. Inverse probability weighting (IPW) was used to adjust for confounders.
resultsAfter IPW adjustment, early APAP use was significantly associated with higher 28-day ICU mortality (HR: 1.70, 95% CI: 1.26-2.3), and elevated risks for all secondary outcomes. Subgroup analyses indicated higher mortality risks in patients with cancer, AKI and sepsis. Total bilirubin levels were identified as a potential predictor of mortality risk.
conclusionsEarly APAP administration in critically ill cirrhotic patients is associated with increased mortality. These findings underscore the need for caution when prescribing APAP in this high-risk population and highlight the importance of further prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.